After serving as a longtime provider of screening assays and instruments for diagnosing cancer, BD is broadening its reach in oncology by acquiring tests that monitor patients for recurrence following treatment.
The medtech company has bought Cytognos, a Spain-based developer of blood tests for tracking minimal residual disease—or the minuscule amounts of cancer cells left floating in the bloodstream while a patient is in remission.
The objective of the deal, made for an undisclosed amount, is to expand BD’s portfolio of flow-cytometry-powered diagnostics for blood cancers including lymphoma, leukemia and multiple myeloma. The transaction covers immune system assessment tests and informatics solutions for oncologists as well.
The acquisition also carries BD into a growing research space of supersensitive tests for minimal residual disease—where companies such as Illumina’s Grail and Exact Sciences’ Thrive Earlier Detection, among many others, are developing their own diagnostics focused on the repeated screening of cancer patients to track the effects of therapy.
“As the understanding and treatment of cancer evolves and improves, the importance of monitoring post remission cancer survivors has become paramount to improve patient outcomes,” Puneet Sarin, worldwide president of BD Biosciences, said in a statement.
Cytognos, previously a division of Spanish diagnostics company Vitro, will also grant BD exclusive access to a series of assays previously licensed from the EuroFlow Consortium, an independent network of hematology and immunology researchers from more than 20 universities and hospitals on the continent.
These flow cytometry tests would be added on top of ones that BD has procured from EuroFlow through its own 12-year licensing collaboration with the group.
Meanwhile, the 25-year-old Cytognos-owned diagnostic products have yet to undergo FDA review or enter the U.S. market; they previously have been available in Europe under a CE mark and in other countries.
by Conor Hale
Source: fiercebiotech.com
A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.
Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.
Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”
